Glaukos (NYSE:GKOS) shares posted second-quarter financial results that came in well ahead of the consensus revenue forecast.
Shares of GKOS remained relatively unmoved at $74.72 apiece after the market closed today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished the day down 1.1%.
The Aliso Viejo-based ophthalmic medical technology company posted losses of $32.8 million. That amounts to 68¢ per share on sales of $80.4 million for the three months ended June 30, 2023.
Glaukos posted a nearly $13 million bottom-line gain on sales growth of 10.6%.
Adjusted to exclude one-time items, losses per share came in at 55¢, equalling Wall Street forecasts. Sales beat expectations of $74.7 million.
“Our record second quarter results highlighted by double-digit topline growth reflect the successful execution of our commercial strategies thus far in 2023,” said Thomas Burns, Glaukos chair and CEO. “We continue to prudently invest in and advance our robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.”
Glaukos expects revenues to range between $304 million and $308 million in 2023.